Impact of Adherence to Concomitant Gastroprotective Therapy on Nonsteroidal-Related Gastroduodenal Ulcer Complications

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 11, 2006, Pages

  Goldstein, Jay L ^a   Howard, Kimberly B ^b   Walton, Surrey M ^a   Mclaughlin, Trent P ^c   Kruzikas, Denise T ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b PFIZER INC   (United States)

^c Wolters Kluwer   (United States)

^d NDC Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ANALYTIC METHOD; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ESOPHAGITIS; FEMALE; GASTRITIS; GASTRODUODENAL ULCER; GASTROINTESTINAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PEPTIC ULCER; RISK; RISK FACTOR; UPPER GASTROINTESTINAL BLEEDING;

EID: 33750796675     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.08.016     Document Type: Article

References (50)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46 (2002) 328-346
2. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43 (2000) 1905-1915
3. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999) 1888-1899
4. Scheiman J.M. Gastrointestinal outcomes: evidence for risk reduction in patients using coxibs. Am J Manag Care 8 (2002) S518-S528
5. Scheiman J.M., and Fendrick A.M. NSAIDs without a prescription: over-the-counter access, under-counted risks. Am J Gastroenterol 97 (2002) 2159-2161
6. Blot W.J., Fischer T., Nielsen G.L., et al. Outcome of upper gastro-intestinal bleeding and use of ibuprofen versus paracetamol. Pharm World Sci 26 (2004) 319-323
7. Ekstrom P., Carling L., Wetterhus S., et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 31 (1996) 753-758
8. Hawkey C.J., Karrasch J.A., Szczepanski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338 (1998) 727-734
9. Yeomans N.D., Tulassay Z., Juhasz L., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338 (1998) 719-726
10. Agrawal N.M., Caldwell J., Kivitz A.J., et al. Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther 21 (1999) 659-674
11. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
12. Taha A.S., Hudson N., Hawkey C.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334 (1996) 1435-1439
13. Robinson M.G., Griffin Jr. J.W., Bowers J., et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 34 (1989) 424-428
14. Ehsanullah R.S., Page M.C., Tildesley G., et al. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 297 (1988) 1017-1021
15. Goldstein J.L., Eisen G., Stenson W., et al. Celecoxib significantly reduces gastrointestinal-related healthcare resource utilization compared to NSAIDs: SUCCESS-1 in osteoarthritis (OA) trial. (abstr). Arthritis Rheum 44 Suppl (2001) 503
16. Goldstein J.L., Silverstein F.E., Agrawal N.M., et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 95 (2000) 1681-1690
17. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
18. Bombardier C., Laine L., Reicin A., et al., VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
19. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
20. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
21. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 127 (2004) 1038-1043
22. Lai K.C., Chu K.M., Hui W.M., et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118 (2005) 1271-1278
23. American Pain Society. Guideline for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis (2002), American Pain Society, Glenview, IL
24. Lanza F.L., and Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 93 (1998) 2037-2046
25. Inadomi J.M., and Fendrick A.M. PPI use in the OTC era: who to treat, with what, and for how long?. Clin Gastroenterol Hepatol 3 (2005) 208-215
26. Dubois R.W., Melmed G.Y., Henning J.M., et al. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 19 (2004) 197-208
27. Abraham N.S., El Serag H.B., Johnson M.L., et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 129 (2005) 1171-1178
28. Simon L.S. Risk factors and current NSAID use. J Rheumatol 26 (1999) 1429-1431
29. Laine L., Bombardier C., Hawkey C.J., et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 123 (2002) 1006-1012
30. Gabriel S.E., Jaakkimainen L., and Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115 (1991) 787-796
31. Shorr R.I., Ray W.A., Daugherty J.R., et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 153 (1993) 1665-1670
32. Piper J.M., Ray W.A., Daugherty J.R., et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 114 (1991) 735-740
33. Singh G., and Rosen Ramey D. NSAID-induced gastrointestinal complications: the ARAMIS perspective 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol 51 Suppl (1998) 8-16
34. Sturkenboom M.C., Burke T.A., Dieleman J.P., et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 42 Suppl 3 (2003) iii23-iii31
35. Sturkenboom M.C., Burke T.A., Tangelder M.J., et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 18 (2003) 1137-1147
36. Rosenow III E.C. Patients' understanding of and compliance with medications: the sixth vital sign?. Mayo Clin Proc 80 (2005) 983-987
37. Makaryus A.N., and Friedman E.A. Patients' understanding of their treatment plans and diagnosis at discharge. Mayo Clin Proc 80 (2005) 991-994
38. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 (2005) 487-497
39. D'Hoore W., Sicotte C., and Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 32 (1993) 382-387
40. Von Korff M., Wagner E.H., and Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 45 (1992) 197-203
41. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105 (1998) 31S-38S
42. Graham D.Y., Agrawal N.M., Campbell D.R., et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162 (2002) 169-175
43. Agrawal N.M., Campbell D.R., Safdi M.A., et al., NSAID-Associated Gastric Ulcer Study Group. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. Arch Intern Med 160 (2000) 1455-1461
44. Patrono C., Coller B., FitzGerald G.A., et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 234S-264S
45. Patrono C., Bachmann F., Baigent C., et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 25 (2004) 166-181
46. Patrono C., Garcia Rodriguez L.A., Landolfi R., et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 (2005) 2373-2383
47. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
48. Kruzikas D.T., Walton S.M., McLaughlin T., et al. Use of gastroprotective agents (GPAs) among patients receiving nonsteroidal anti-inflammatory drugs (NSAIDs). (abstr M986). Gastroenterology 128 Suppl 2 (2005) A285
49. Rahme E., Barkun A.N., Toubouti Y., et al. Do proton pump inhibitors (PPIs) infer additional gastrointestinal protection in patients given celecoxib?. A retrospective cohort study. (abstr). Gastroenterology 128 Suppl 2 (2005) A139
50. Chan F.K., Wong V.W., Suen B.Y., et al. Proton pump inhibitor plus a COX-2 inhibitor for the prevention of recurrent ulcer bleeding in patients with arthritis: a double-blind, randomized trial. (abstr 732). Gastroenterology 130 Suppl 2 (2006) A105